logo Click here for the Chao Family Comprehensive Cancer Center Home Page Click here for the UC Irvine Home Page
 
 
 
 

DISEASE ORIENTED TEAMS

What is a Disease-Oriented Team (DOT)?

A Disease-Oriented Team (DOT) is a multidisciplinary group of clinical, basic and translational researchers who collaborate around a specific anatomic cancer area to further the translation of Cancer Center discoveries (e.g. new targets, biomarkers, drugs, biological agents, diagnostic and therapeutic devices) through the pipeline towards interventional clinical trials. Because of their collective expertise, DOTs steward the Cancer Center's clinical research efforts, managing the clinical trials portfolio around the following principles: scientific merit, soundness of trial design, accrual potential, and likelihood for correlative translational science.

What does a DOT do?

  • Facilitate the translation of scientific discoveries to address specific types of cancer
  • Promote multidisciplinary collaboration to address disease-specific questions
  • Determine interest in and commitment to a trial and the potential to accrue
  • Ensure adequate internal review of scientific quality and feasibility of clinical trials, and oversees prioritization of protocols
  • Review clinical research portfolio and develops and brings forward new trials, including investigator-initiated trials
  • Catalyze new multi-investigator, multidisciplinary preclinical and clinical translational research

Have a clinical study you'd like to launch?

All clinical studies in cancer must undergo a feasibility review by the corresponding DOT or Tumor Board. To submit a study for review, download and complete the application and email to CancerCenter_Committees@health.uci.edu.

Our current DOTs

For meeting times and locations, please see the administrative contacts listed below.

Breast Oncology »

Co-Leaders:

Devon Lawson, PhD
Erin Lin, DO
Ritesh Parajuli, MD

Meeting Frequency: Monthly, typically the last Tuesday, at the UC Irvine Medical Center.

Gastrointestinal Oncology »

Co-Leaders:

Rob Edwards, MD, PhD
Michael Stamos, MD
Jason Zell, DO

Meeting Frequency: Monthly, the 3rd or 4th Tuesday, at the UCI Medical Center.

Genitourinary Oncology »

Co-Leaders:

Thomas Ahlering, MD
Michael McClelland, PhD

Meeting Frequency: Monthly, the 3rd or 4 Wednesday or the 2nd or 4th Friday, at the UC Irvine Medical Center.

Gynecologic Oncology »

Co-Leaders:

Krishnansu Tewari, MD
Lydia Su, PhD

Meeting Frequency: Monthly, the last Friday, at the UC Irvine Medical Center.

Hematologic Malignancies »

Co-Leaders:

Angela Fleischman, MD, PhD
Deepa Jeyakumar, MD

Meeting Frequency: Monthly, the first Thursday, at the UC Irvine Medical Center.

Neuro-Oncology »

Co-Leaders:

Daniela Bota, MD, PhD
Frank Hsu, MD, PhD

Meeting Frequency: Monthly, typically the 1st Friday, at the UC Irvine Medical Center.

Skin Cancer »

Co-Leaders:

Kristin Kelly, MD
Ken Linden, MD
Anthony Durkin, PhD

Meeting Frequency: Monthly, the 1st or 2nd Monday or 2nd Wednesday, alternating between the UC Irvine Medical Center and the main campus in Irvine.

Administrative Contacts

For more information on the DOTs, please contact:

Elizabeth Forbes
Assistant Protocol Review & Monitoring Coordinator
Email: elizabeth.forbes@uci.edu
Phone: 714-456-3995

spacer